InvestorsHub Logo

jimmy667

10/19/19 9:34 AM

#215330 RE: ignatiusrielly35 #215319

This post exhibits clear vision of seeing things as they really are. This is the precise reason I never invest in tradionally funded biotech that follow the traditional financing options of Yearly or biyearly secondary Wall Street offerings to the big boy vulture investors. LPC ELOC that Anavex has in place is far superior. Also subsctipion rights plan as GALT did is also superior as the new shares get sold to existing shareholders not shorts.
The Anti takeover provisions Anavex passed last year is also in effect a subsctipion rights plan limited to those shareholders that owned the stock on the specified date which a believe was a date back in Feb 2017 thereby eliminating shorts from participating in it.